III. Specification Amendments

(¶ on Page 1, line 3)

This application is a continuation of U.S. Pat. App. No. 08/619,645, now U.S. Pat. No. 5,736,507.

(¶ on Page 7, lines 19-24)

Very suitable peptides to be used in a pharmaceutical composition according to the invention are the peptides comprising an amino acid sequence give in SEQ ID NO:1(FGRSFTLAS), SEQ ID NO:2(FTLASSETG), SEQ ID NO3(YDDQESVKS), SEQ ID NO:4(FSKIASNTQ), SEQ ID NO:5(PTFGRSFTLASSE), SEQ ID NO:6([PTFGRSFTLASSETGVG]RSFTLASSETGVG), SEQ ID NO:7(VGYDDQESVKSKV), and SEQ ID NO:8(SQRFSKIASNTQSR).

(¶ on Page 4, lines 20-30)

In contrast to the effect [effect] seen with CII, HC gp-39 does not downmodulate collagen induced arthritis when tested in a scheme designed to prevent the induction of this disease (application on days -15, -10 and -5). Thus, in this situation HC gp-39 is not effective in downmodulation of arthritis activity when using a pretreatment protocol. Surprisingly, however, HC gp-39 is highly effective in treatment of the autoimmune condition induced with CII when given on days 20, 25 and 30 following arthritis induction. Therefore, when HC gp-39 was given in a therapeutic application schedule that is highly relevant to the clinical situation in which patients present themselves to the doctor with ongoing automimmune disease, arthritis activity was strongly inhibited. This inhibition of arthritis activity as a result of application of HC gp-39 was much stronger than the effect seen with the antigen used in the induction of disease, collagen type II.